Spruce Biosciences Stock Today
| SPRB Stock | USD 0.55 0.02 3.77% |
Performance6 of 100
| Odds Of DistressOver 66
|
Spruce Biosciences is trading at 0.55 as of the 27th of November 2024, a 3.77 percent increase since the beginning of the trading day. The stock's open price was 0.53. Spruce Biosciences has more than 66 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Spruce Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of May 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of October 2020 | Category Healthcare | Classification Health Care |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 41.3 M outstanding shares of which 232.77 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover. More on Spruce Biosciences
Moving against Spruce Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Spruce Stock Highlights
| Executive Chairman | Michael Grey | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSpruce Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Spruce Biosciences' financial leverage. It provides some insight into what part of Spruce Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Spruce Biosciences (SPRB) is traded on NASDAQ Exchange in USA. It is located in 611 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 29 people. Spruce Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.88 M. Spruce Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.3 M outstanding shares of which 232.77 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover.
Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Spruce Biosciences Probability Of Bankruptcy
Ownership AllocationSpruce Biosciences shows a total of 41.3 Million outstanding shares. 30% of Spruce Biosciences outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Spruce Ownership Details
Spruce Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 77.1 K | |
| Lion Point Capital, Lp | 2024-09-30 | 75 K | |
| Northern Trust Corp | 2024-09-30 | 74.9 K | |
| State Street Corp | 2024-06-30 | 64.4 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 45.7 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 40 K | |
| Tower Research Capital Llc | 2024-06-30 | 33.1 K | |
| Jane Street Group Llc | 2024-06-30 | 30.8 K | |
| Two Sigma Investments Llc | 2024-09-30 | 23.4 K | |
| Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | |
| The Carlyle Group Inc | 2024-09-30 | 2.9 M |
Spruce Biosciences Historical Income Statement
Spruce Stock Against Markets
Spruce Biosciences Corporate Management
| CPA CPA | Pres CFO | Profile | |
| MD III | Chief Officer | Profile | |
| Libbie MBA | Chief Officer | Profile | |
| P Ramtin | Senior Operations | Profile | |
| Heidi MPH | Senior Quality | Profile | |
| MPH MD | CEO Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.